Physician profile
Kenneth Lieberman
NPI 1174582951
$143,622.66
in general payments reported to CMS, 2019-2025
21 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,511 · 2020: $21K · 2021: $5,421 · 2022: $6,089 · 2023: $33K · 2024: $29K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $55K · Consulting Fee: $25K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,683 · Travel and Lodging: $8,658 · Food and Beverage: $4,168 · Education: $13.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $55,275.00 |
| Consulting Fee | $24,676.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,682.50 |
| Travel and Lodging | $8,657.66 |
| Food and Beverage | $4,168.28 |
| Education | $13.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $62,918.72 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $23,476.44 | 2019-2025 | Ultomiris |
| Travere Therapeutics, INC. | $22,518.68 | 2019-2025 | Filspari, Thiola |
| Apellis Pharmaceuticals, INC. | $12,878.23 | 2022-2025 | Empaveli |
| Horizon Therapeutics Plc | $10,840.00 | 2019-2023 | Procysbi |
| Novartis Pharmaceuticals Corporation | $7,153.02 | 2019-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,640.00 | 2024 | |
| Novo Nordisk INC | $460.00 | 2022 | |
| Aurinia Pharma U.S., INC. | $133.19 | 2024 | Lupkynis |
| Vertex Pharmaceuticals Incorporated | $129.16 | 2022 | |
| Sanofi-Aventis U.S. LLC | $121.07 | 2023 | |
| Genzyme Corporation | $120.29 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $105.39 | 2019 | |
| Nxstage Medical, INC. | $77.98 | 2025 | Nxstage System One |
| Novo Nordisk Health Care Ag | $50.49 | 2023 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.